Jack H. Ladenson, PhD

Oree M. Carroll and Lillian B. Ladenson Professor of Clinical Chemistry

Additional Titles

  • Professor, Pathology & Immunology
  • Professor, Internal Medicine


  • BS: Pennsylvania State University, University Park, PA (1964)
  • PhD: Analytical Chemistry with Professor William C. Purdy: University of Maryland, College Park, MD (1971)
  • Post-doctoral training in Clinical Chemistry with George N. Bowers, Jr., MD, Robert B. McComb, PhD and Robert W. Burnett, PhD: Hartford Hospital, Hartford, CT (1970-1972)

Board Certifications

  • Certified in Clinical Chemistry by the American Board of Clinical Chemistry, 1974


  • American Association for Clinical Chemistry (AACC) Award for Outstanding Contributions in Education, 1989
  • Outstanding Contributions to Clinical Chemistry Award, AACC, 1994
  • Gerald T. Evans Award of the Academy of Clinical Laboratory Physicians and Scientists (ACLPS), 1999
  • AACC Award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research, 2002
  • Distinguished Service Award – Washington University Medical Center Alumni Association, 2003
  • Presidential Citation from Susan Evans, Ph.D., President of The American Association for Clinical Chemistry (AACC) for Pathologists Overseas work in developing countries, 2003
  • Mentor of the Year Award of the Academic Women’s Network of Washington University School of Medicine, 2004
  • Cotlove Award Lecturer; ACLPS, 2006
  • WUSM Distinguished Community Service Award, 2010
  • Inaugural Recipient of the Chancellor’s Award for Innovation and Entrepreneurship, Washington University in St. Louis, 2010
  • IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics (Initial Winner), 2017
  • 2nd Century Award, Washington University School of Medicine, 2018

Clinical Interests

  • Clinical Chemistry

Research Interests

My laboratory has long been interested in the development of rapid, accurate techniques for the diagnosis and/or prognosis of human disease and the enhancement of basic or clinical research. Our previous work concerned the diagnosis of myocardial infarction (MI). A monoclonal antibody specific to the creatine kinase-MB (CK-MB) isoenzyme was developed which did not react with CK-BB, CK-MM or mitochondrial CK. This antibody was then widely utilized in virtually all commercially available assays for CK-MB. The work was extended to the development of the first assays for Troponin I and myoglobin. We have also developed a monoclonal antibody to calmodulin, a highly conserved protein throughout animal species and plants which has proved to be a very useful reagent for research investigations. Our current work involves the development and validation of assays to improve the diagnosis of renal damage and the diagnosis and prognosis of neurodegenerative diseases such as Alzheimer’s.

For the last twenty years, I have run the clinical pathology programs for Pathologists Overseas, an organization whose mission is to help improve and provide affordable pathology and clinical laboratory services to under-served patients worldwide: http://www.pathologistsoverseas.com/. This has led to a variety of short- and long-term projects especially in the countries of Eritrea and Bhutan. These efforts, sustained by volunteers, have the goal of upgrading laboratory services, upgrading the training of laboratory personnel, extending laboratory testing to regional hospitals, clinician education, and helping to develop standardized national laboratory systems.

Diagnostic Expertise

  • Clinical Chemistry
  • Biomarkers
  • Laboratory Medicine in developing countries


Pub Med Search

Heart Antibody Work

Vaidya HC, Maynard Y, Ladenson JH:  Direct measurement of creatine kinase-MB activity in serum after extraction with a monoclonal antibody specific to the MB isoenzyme.  Clin Chem  1986;32:657.

Bodor GS, Porter S, Landt Y, Ladenson J:  Development of monoclonal antibodies for an assay of cardiac troponin-I and preliminary results in suspected cases of myocardial infarction.  Clin Chem 1992;38:2203-2214.

Adams JE III, Sicard GA, Allen BT, Bridwell KH, Lenke LG, Davila-Roman VG, Bodor GS, Ladenson JH, Jaffe AS:  Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I.  New Engl J Med 1994;330:670-674.

Pathologists Overseas

Ladenson JH, Scott MG, Klarkowski D, Seyoum M:  The Use of a Major Medical Center Clinical Laboratory as a Reference Laboratory for a Developing Country.  Clin Chem 2003;49(1):162-166

Scott MG, Morin S, Hock KG, Seyoum M, Ladenson JH.  Establishing a simple and sustainable quality assurance program and clinical chemistry services in Eritrea.  Clin Chem.  2007;53(11):1945-1953

Kidney Markers

Gaut JP, Crimmins DL, Ohlendorf MF, Lockwood CM, Griest TA, Brada NA, Hoshi M, Sato B, Hotchkiss RS, Jain S, Ladenson JH.  Development of an Immunoassay for the Kidney-Specific Protein myo-Inositol Oxygenase, a Potential Biomarker of Acute Kidney Injury.  Clin Chem 2014; 60(5):737-746

Brain Biomarkers

Laterza OF, Modur VR, Crimmins DL, Olander JV, Landt Y, Lee JM, Ladenson JH:  Identification of novel brain biomarkers.  Clinical Chemistry; 2006;52(9):1713-1721

Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM.   CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer’s disease.  Neurology2012;78(10):709-19

Fagan AM, Xiong C, Jasielec MS, Bateman RJ, Goate AM, Benzinger TLS, Ghetti, B, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor, MN, Salloway S, Schofield PR, Sperling RA, Marcus D, Cairns NJ, Buckles VD, Ladenson JH, Morris, JC, Holtzman DM. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s Disease. Science Translational Medicine 2014 March 5; 6(226):226ra30

Crimmins DL, Herries EM, Ohlendorf MF, Brada NA, Garbett NC, Zipfel GJ, Schindler SE, Ladenson JH.  Double Monoclonal Immunoassay for Quantifying Human Visinin-Like Protein-1 in CSF.  Clin Chem 2017 63(2): 603-604

Tarawneh R, D’Angelo G, Crimmins D, Herries E, Griest T, Fagan AM, Zipfel GJ, Ladenson JH, Morris, JC, Holtzman DM.  The Diagnostic and Prognostic Utility of the Synaptic Marker, Neurogranin, in Alzheimer Disease.  JAMA Neurol 2016  73(5): 561-71

Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Ladenson JH, et al.  Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer’s disease.  Alzheimer’s & Dementia 2019 (In press)

Office Location: BJC-IH Building, Room 5807

Ann Winn